Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
CE

NASDAQ · CELU

Celularity Inc.

Healthcare · Biotechnology

$0.80

Down-$0.05 (-5.79%)

Updated Nov 2, 2026, 6:48 AM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
39.93M
P/E ratio
-0.54
Dividend yield
0.00%
52-week range
$0.56 – $2.55
Volume
181.85K
Avg. volume
124.95K

Price performance · CELU

CELU price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

CELU closed at $0.80 after 20 trading sessions, down 53.21% for the selected period.

Last close
$0.80
Period change
-53.21%
Period low
$0.75
Period high
$1.71
Daily close
View OHLC price history
CELU OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$0.82$0.8689$0.80$0.8001181.85K
Oct 29, 2026$0.98$0.98$0.8338$0.8493496.84K
Oct 28, 2026$0.821$1.04$0.7822$0.9401350.94K
Oct 27, 2026$0.80$0.8683$0.78$0.7902219.29K
Oct 26, 2026$0.964$1.00$0.66$0.75629K
Oct 23, 2026$1.06$1.1422$0.9109$0.9777145.35K
Oct 22, 2026$1.07$1.08$1.01$1.05144.73K
Oct 21, 2026$1.31$1.31$1.02$1.02204.71K
Oct 20, 2026$1.16$1.30$1.16$1.2660.14K
Oct 19, 2026$1.29$1.29$1.1214$1.1687.79K
Oct 16, 2026$1.33$1.33$1.22$1.2564.07K
Oct 15, 2026$1.28$1.35$1.27$1.3330.65K
Oct 14, 2026$1.39$1.41$1.28$1.3180.19K
Oct 13, 2026$1.45$1.55$1.40$1.4250.37K
Oct 12, 2026$1.56$1.57$1.4611$1.4743.73K
Oct 9, 2026$1.46$1.57$1.4513$1.5653.2K
Oct 8, 2026$1.46$1.50$1.43$1.46103.71K
Oct 7, 2026$1.53$1.57$1.47$1.4768.94K
Oct 6, 2026$1.70$1.7693$1.54$1.58260.95K
Oct 5, 2026$1.60$1.80$1.57$1.71282.13K

Latest CELU news

The latest Smart Investors Daily articles mentioning CELU.

Stock researchCompany · Overview

CELU research

Overview

Company profile and research snapshot.

Company profile

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$3.00
Implied upside
—
Analysts
—
CELU recent ratings
DateFirmRatingTarget
Sep 9, 2025WBB SecuritiesBuy—
Aug 18, 2025WBB SecuritiesSpeculative Buy—
Jan 30, 2023Morgan StanleyUnderweight—
Jan 30, 2023HC Wainwright & Co.Buy—
Dec 22, 2022OppenheimerPerform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 29, 2026

Celularity and Vesalius Longevity Labs Sign Exclusive Collaboration for Peptual® Peptide APIs Manufactured in the United States

FLORHAM PARK, N.J. & SCOTTSDALE, Ariz., October 29, 2026--Celularity Inc. (Nasdaq: CELU) ("Celularity"), a longevity-focused regenerative and cellular medicine company, and Vesalius Longevity Labs Inc. ("Vesalius"), a leading, global peptide and longevity brand, today announced that they have entered into an exclusive manufacturing agreement to establish a dedicated, first-of-its-kind, U.S. final stage API manufacturing and supply platform for Vesalius’s Peptual-branded active pharmaceutical ing

Yahoo · Oct 22, 2026

Celularity Regains Compliance with Nasdaq Periodic Reporting Requirement

Nasdaq closes reporting deficiency following filing of second-quarter 2026 Form 10-QFLORHAM PARK, N.J., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced that it received written confirmation from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) that Celularity has regained compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic

Benzinga · Oct 22, 2026

Celularity Regains Nasdaq Compliance

Celularity Inc. (Nasdaq: CELU) ("Celularity"), a longevity-focused regenerative and cellular medicine company, today announced that it received written confirmation from the Listing Qualifications Staff of The

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By